This study is not yet accepting patients

Pilot Study of an Adapted Partner Navigation Intervention Booster Session for Sustained Healthcare Engagement Among People Who Inject Drugs

a study on Hepatitis C Opioid Use Substance Abuse Drug Use Healthcare Access Harm Reduction

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Francisco, California
Dates
study started
study ends around
Principal Investigator
by Meghan Morris, PhD, MPH
Headshot of Meghan Morris
Meghan Morris

Description

Summary

This study builds upon an ongoing NIH-funded randomized controlled trial (R01DA053325) evaluating a Partner Navigation Intervention to increase hepatitis C virus (HCV) treatment initiation among young adult people who inject drugs (PWID) and their injecting partners in San Francisco. The proposed research includes secondary analyses of existing trial data, additional survey measures, qualitative interviews, and a pilot intervention adaptation.

The study has two primary objectives. First, it examines how racialized discrimination (structural, interpersonal, and internalized) affects HCV treatment initiation and dyadic partner support processes within injecting partnerships. Second, it evaluates whether a brief, adapted "booster" partner navigation session delivered at HCV treatment completion can improve engagement in ongoing healthcare.

Participants include adults (≥18 years) who inject drugs and have been diagnosed with HCV, along with their primary injecting partners. Study activities include longitudinal surveys, qualitative interviews with a subset of participants, and a pilot intervention session with follow-up evaluation.

This research addresses critical gaps in understanding how social relationships and structural inequities influence healthcare engagement among PWID. Findings will inform culturally responsive adaptations to dyadic interventions and improve continuity of care in a population disproportionately affected by HCV and systemic barriers to healthcare.

Keywords

HEPATITIS C (HCV), Opioid Use Disorder, Substance Use Disorder (SUD), Drug Use Disorders, Healthcare Access, Harm Reduction, People who inject drugs (PWID), Partner navigation, Dyadic intervention, Post-treatment healthcare engagement, Behavioral intervention, HCV treatment, Injecting partnerships, Feasibility pilot, Substance use, Hepatitis C, Opioid-Related Disorders, Substance-Related Disorders, Partner navigation intervention booster session, Partner Navigation Booster Session

Eligibility

You can join if…

Open to people ages 18 years and up

For index participants:

  • 18 years of age or older at enrollment
  • History of injecting drug use
  • Completed HCV treatment within the past 3 months
  • Report a primary injecting partner willing to participate
  • Willing and able to provide informed consent
  • English or Spanish speaking

For primary injecting partners:

  • Primary injecting partner of an enrolled index participant:
  • 18 years of age or older at enrollment
  • Willing and able to provide informed consent
  • English or Spanish speaking
  • has context menu

You CAN'T join if...

For both index participants and injecting partners:

Location

  • Quaker Meeting House
    San Francisco California 94103 United States

Lead Scientist at UCSF

  • Meghan Morris, PhD, MPH
    My professional activities are grounded in engaging diverse partners in the development of evidence-based policy change to reduce social inequalities and improve health among underserved communities. As a Professor, my research focuses on applying epidemiological methods to study the impact of individual, social, and structural factors on disease transmission within marginalized populations.

Details

Status
not yet accepting patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Francisco
ID
NCT07631559
Study Type
Interventional
Participants
Expecting 50 study participants
Last Updated